Skip to main content
Top
Published in: International Journal of Legal Medicine 6/2011

01-11-2011 | Original Article

Deaths involving contraindicated and inappropriate combinations of serotonergic drugs

Authors: Jennifer L. Pilgrim, Dimitri Gerostamoulos, Olaf H. Drummer

Published in: International Journal of Legal Medicine | Issue 6/2011

Login to get access

Abstract

In the Australian state of Victoria, all fatalities that were recorded from 2002 through to 2008 involving the use of certain serotonin active drugs (tramadol, venlafaxine, fluoxetine, sertraline, citalopram and paroxetine), were reviewed to assess the incidence of contraindicated or ill advised drug combinations. More than 1,000 were identified of which 326 cases formed the basis of this study. These cases involved contraindicated or inappropriate drug combinations that can lead to adverse drug reactions (ADRs) and subsequent fatal toxicity. Of these, 46% were drug-related, 35% were a result of natural disease and 13% were classified as external injury cases. The remaining cases were those where the cause of death (COD) was unascertained. Tramadol was the most common drug, usually detected alongside a serotonergic antidepressant (in 20% of cases). Twenty-five (8%) cases involved contraindicated drug combinations while the remainder (301 cases, 92%) involved drug combinations that are associated with adverse interactions ranging from minor to major severity. Of these 326 cases, the Coroner determined 166 cases (51%) to be acts of intentional self-harm or drug misuse, with the remainder unascertained or attributed to natural disease. Very few post-mortem reports and Coroners’ findings made mention of possible ADRs when such combinations were actually present. The majority of cases comprising contraindicated drug combinations involved the combined use of five drugs (24%) at the time of death. A combination of three to five drugs was most common in cases involving inadvisable drug combinations. Combined drug toxicity was the most common COD, with heart disease the most common co-morbidity.
Literature
1.
go back to reference Roughead EE, Lexchin J (2006) Adverse drug events: counting is not enough, action is needed. Med J Aust 184(7):315–316PubMed Roughead EE, Lexchin J (2006) Adverse drug events: counting is not enough, action is needed. Med J Aust 184(7):315–316PubMed
2.
go back to reference Runciman WB, Roughead EE, Semple SJ, Adams RJ (2003) Adverse drug events and medication errors in Australia. Int J Qual Health Care 15(Suppl 1):i49–i59PubMedCrossRef Runciman WB, Roughead EE, Semple SJ, Adams RJ (2003) Adverse drug events and medication errors in Australia. Int J Qual Health Care 15(Suppl 1):i49–i59PubMedCrossRef
3.
4.
go back to reference Birmes P, Coppin D, Schmitt L, Lauque D (2003) Serotonin syndrome: a brief review. CMAJ 168(11):1439–1442PubMed Birmes P, Coppin D, Schmitt L, Lauque D (2003) Serotonin syndrome: a brief review. CMAJ 168(11):1439–1442PubMed
6.
go back to reference Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705–713PubMed Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705–713PubMed
9.
go back to reference Tamblyn RM, McLeod PJ, Abrahamowicz M, Monette J, Gayton DC, Berkson L, Dauphinee WD, Grad RM, Huang AR, Isaac LM, Schnarch BS, Snell LS (1994) Questionable prescribing for elderly patients in Quebec. CMAJ 150(11):1801–1809PubMed Tamblyn RM, McLeod PJ, Abrahamowicz M, Monette J, Gayton DC, Berkson L, Dauphinee WD, Grad RM, Huang AR, Isaac LM, Schnarch BS, Snell LS (1994) Questionable prescribing for elderly patients in Quebec. CMAJ 150(11):1801–1809PubMed
10.
go back to reference Hamilton H, Gallagher P, O’Mahony D (2009) Inappropriate prescribing and adverse drug events in older people. BMC Geriatr 9(1):5PubMedCrossRef Hamilton H, Gallagher P, O’Mahony D (2009) Inappropriate prescribing and adverse drug events in older people. BMC Geriatr 9(1):5PubMedCrossRef
11.
go back to reference Jones JK, Fife D, Curkendall S, Goehring E Jr, Guo JJ, Shannon M (2001) Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 286(13):1607–1609PubMedCrossRef Jones JK, Fife D, Curkendall S, Goehring E Jr, Guo JJ, Shannon M (2001) Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 286(13):1607–1609PubMedCrossRef
12.
go back to reference Stang P, Morris L, Kempf J, Henderson S, Yood MU, Oliveria S (2007) The coprescription of contraindicated drugs with statins: continuing potential for increased risk of adverse events. Am J Ther 14(1):30–40PubMedCrossRef Stang P, Morris L, Kempf J, Henderson S, Yood MU, Oliveria S (2007) The coprescription of contraindicated drugs with statins: continuing potential for increased risk of adverse events. Am J Ther 14(1):30–40PubMedCrossRef
13.
go back to reference Roughead EE, Anderson B, Gilbert AL (2007) Potentially inappropriate prescribing among Australian veterans and war widows/widowers. Intern Med J 37(6):402–405PubMedCrossRef Roughead EE, Anderson B, Gilbert AL (2007) Potentially inappropriate prescribing among Australian veterans and war widows/widowers. Intern Med J 37(6):402–405PubMedCrossRef
14.
go back to reference Ringland C, Mant A, McGettigan P, Mitchell P, Kelman C, Buckley N, Pearson SA (2008) Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data. Br J Clin Pharmacol 66(5):682–688PubMed Ringland C, Mant A, McGettigan P, Mitchell P, Kelman C, Buckley N, Pearson SA (2008) Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data. Br J Clin Pharmacol 66(5):682–688PubMed
15.
go back to reference Pilgrim JL, Gerostamoulos D, Drummer OH (2010) Deaths involving serotonergic drugs. Forensic Sci Int 198(1–3):110–117PubMedCrossRef Pilgrim JL, Gerostamoulos D, Drummer OH (2010) Deaths involving serotonergic drugs. Forensic Sci Int 198(1–3):110–117PubMedCrossRef
16.
go back to reference Gillman PK (2005) Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 95(4):434–441PubMedCrossRef Gillman PK (2005) Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 95(4):434–441PubMedCrossRef
17.
go back to reference Houlihan DJ (2004) Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. Ann Pharmacother 38(3):411–413PubMedCrossRef Houlihan DJ (2004) Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. Ann Pharmacother 38(3):411–413PubMedCrossRef
18.
go back to reference Hernandez JL, Ramos FJ, Infante J, Rebollo M, Gonzalez-Macias J (2002) Severe serotonin syndrome induced by mirtazapine monotherapy. Ann Pharmacother 36(4):641–643PubMedCrossRef Hernandez JL, Ramos FJ, Infante J, Rebollo M, Gonzalez-Macias J (2002) Severe serotonin syndrome induced by mirtazapine monotherapy. Ann Pharmacother 36(4):641–643PubMedCrossRef
19.
go back to reference Gillman PK (2006) A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 59(11):1046–1051PubMedCrossRef Gillman PK (2006) A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 59(11):1046–1051PubMedCrossRef
20.
go back to reference Rahola JG (2001) Antidepressants: pharmacological profile and clinical consequences. Int J Psychiatry Clin Pract 5(1):19–28 Rahola JG (2001) Antidepressants: pharmacological profile and clinical consequences. Int J Psychiatry Clin Pract 5(1):19–28
21.
go back to reference Eap CB, Bertschy G, Powell K, Baumann P (1997) Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol 17(2):113–117PubMedCrossRef Eap CB, Bertschy G, Powell K, Baumann P (1997) Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol 17(2):113–117PubMedCrossRef
22.
go back to reference Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, Kosel M, Baumann P, Eap CB (2002) Paroxetine increases steady-state concentrations of (r)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 22(2):211–215PubMedCrossRef Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, Kosel M, Baumann P, Eap CB (2002) Paroxetine increases steady-state concentrations of (r)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 22(2):211–215PubMedCrossRef
23.
25.
go back to reference Buajordet I, Ebbesen J, Erikssen J, Brors O, Hilberg T (2001) Fatal adverse drug events: the paradox of drug treatment. J Intern Med 250(4):327–341PubMedCrossRef Buajordet I, Ebbesen J, Erikssen J, Brors O, Hilberg T (2001) Fatal adverse drug events: the paradox of drug treatment. J Intern Med 250(4):327–341PubMedCrossRef
26.
go back to reference Shah S, Aslam M, Avery A (2001) A survey of prescription errors in general practice. Pharm J 267:860–863 Shah S, Aslam M, Avery A (2001) A survey of prescription errors in general practice. Pharm J 267:860–863
27.
go back to reference Gleason OC, Yates WR, Philipsen MA, Isbell MD, Pollock BG (2004) Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics 45(1):29–33PubMedCrossRef Gleason OC, Yates WR, Philipsen MA, Isbell MD, Pollock BG (2004) Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics 45(1):29–33PubMedCrossRef
28.
go back to reference Henz S, Maeder MT, Huber S, Schmid M, Loher M, Fehr T (2008) Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions. Nephrol Dial Transplant 23(12):3939–3945PubMedCrossRef Henz S, Maeder MT, Huber S, Schmid M, Loher M, Fehr T (2008) Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions. Nephrol Dial Transplant 23(12):3939–3945PubMedCrossRef
29.
go back to reference Zhang M, Holman CD, Price SD, Sanfilippo FM, Preen DB, Bulsara MK (2009) Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ 338:a2752PubMedCrossRef Zhang M, Holman CD, Price SD, Sanfilippo FM, Preen DB, Bulsara MK (2009) Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ 338:a2752PubMedCrossRef
30.
go back to reference Mangoni A, Jackson S (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14PubMedCrossRef Mangoni A, Jackson S (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14PubMedCrossRef
31.
go back to reference Spinewine A, Schmader K, Barber N, Hughes C, Lapane K, Swine C, Hanlon J (2007) Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 370:173–184PubMedCrossRef Spinewine A, Schmader K, Barber N, Hughes C, Lapane K, Swine C, Hanlon J (2007) Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 370:173–184PubMedCrossRef
33.
go back to reference Australian Bureau of Statistics (2003) Drug-induced death, Australia, 1991–2001. Canberra, Australia Australian Bureau of Statistics (2003) Drug-induced death, Australia, 1991–2001. Canberra, Australia
34.
go back to reference Butzbach DM (2009) The influence of putrefaction and sample storage on post-mortem toxicology results. Forensic Sci Med Pathol 6(1):35–45PubMedCrossRef Butzbach DM (2009) The influence of putrefaction and sample storage on post-mortem toxicology results. Forensic Sci Med Pathol 6(1):35–45PubMedCrossRef
35.
go back to reference Barnhart FE, Bonnell HJ, Rossum KM (2001) Post-mortem drug redistribution. Forensic Sci Rev 13(2):101–129 Barnhart FE, Bonnell HJ, Rossum KM (2001) Post-mortem drug redistribution. Forensic Sci Rev 13(2):101–129
36.
go back to reference Clarot F, Goulle JP, Vaz E, Proust B (2003) Fatal overdoses of tramadol: is benzodiazepine a risk factor of lethality? Forensic Sci Int 134(1):57–61PubMedCrossRef Clarot F, Goulle JP, Vaz E, Proust B (2003) Fatal overdoses of tramadol: is benzodiazepine a risk factor of lethality? Forensic Sci Int 134(1):57–61PubMedCrossRef
37.
go back to reference Goldberg RM, Mabee J, Chan L, Wong S (1996) Drug–drug and drug–disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 14(5):447–450PubMedCrossRef Goldberg RM, Mabee J, Chan L, Wong S (1996) Drug–drug and drug–disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 14(5):447–450PubMedCrossRef
38.
go back to reference Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB (2005) Interaction of serotonergic antidepressants and opioid analgesics: is serotonin syndrome going undetected? J Am Med Dir Assoc 6(4):265–269PubMedCrossRef Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB (2005) Interaction of serotonergic antidepressants and opioid analgesics: is serotonin syndrome going undetected? J Am Med Dir Assoc 6(4):265–269PubMedCrossRef
39.
go back to reference Mahlberg R, Kunz D, Sasse J, Kirchheiner J (2004) Serotonin syndrome with tramadol and citalopram. Am J Psychiatry 161(6):1129PubMedCrossRef Mahlberg R, Kunz D, Sasse J, Kirchheiner J (2004) Serotonin syndrome with tramadol and citalopram. Am J Psychiatry 161(6):1129PubMedCrossRef
40.
go back to reference Launiainen T, Rasanen I, Vuori E, Ojanpera I (2010) Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int J Legal Med. doi:10.1007/s00414-010-0461-5 Launiainen T, Rasanen I, Vuori E, Ojanpera I (2010) Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int J Legal Med. doi:10.​1007/​s00414-010-0461-5
41.
go back to reference Dams R, Benijts TH, Lambert WE, Van Bocxlaer JF, Van Varenbergh D, Van Peteghem C, De Leenheer AP (2001) A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. J Anal Toxicol 25(2):147–151PubMed Dams R, Benijts TH, Lambert WE, Van Bocxlaer JF, Van Varenbergh D, Van Peteghem C, De Leenheer AP (2001) A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. J Anal Toxicol 25(2):147–151PubMed
42.
go back to reference Marino MR, Langenbacher M, Ulderman HD (1996) Interaction of nefazodone and fluoxetine. Clin Pharmacol Ther 59:180CrossRef Marino MR, Langenbacher M, Ulderman HD (1996) Interaction of nefazodone and fluoxetine. Clin Pharmacol Ther 59:180CrossRef
43.
go back to reference Martinelli V, Bocchetta A, Palmas AM, Del Zompo M (1993) An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol 36(6):615–616PubMed Martinelli V, Bocchetta A, Palmas AM, Del Zompo M (1993) An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol 36(6):615–616PubMed
44.
go back to reference Bertschy G, Vandel S, Vandel B, Allers G, Volmat R (1991) Fluvoxamine-tricyclic antidepressant interaction. An accidental finding. Eur J Clin Pharmacol 40(1):119–120PubMedCrossRef Bertschy G, Vandel S, Vandel B, Allers G, Volmat R (1991) Fluvoxamine-tricyclic antidepressant interaction. An accidental finding. Eur J Clin Pharmacol 40(1):119–120PubMedCrossRef
45.
go back to reference Weschules DJ, Bain KT, Richeimer S (2008) Actual and potential drug interactions associated with methadone. Pain Med 9(3):315–344PubMedCrossRef Weschules DJ, Bain KT, Richeimer S (2008) Actual and potential drug interactions associated with methadone. Pain Med 9(3):315–344PubMedCrossRef
46.
go back to reference Cascorbi I (2003) Pharmacogenetics of cytochrome p4502d6: genetic background and clinical implication. Eur J Clin Investig 33(Suppl 2):17–22CrossRef Cascorbi I (2003) Pharmacogenetics of cytochrome p4502d6: genetic background and clinical implication. Eur J Clin Investig 33(Suppl 2):17–22CrossRef
47.
go back to reference Gardiner SJ, Begg EJ (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58(3):521–590PubMedCrossRef Gardiner SJ, Begg EJ (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58(3):521–590PubMedCrossRef
48.
go back to reference Kollek R, van Aken J, Feuerstein G, Schmedders M (2006) Pharmacogenetics, adverse drug reactions and public health. Community Genet 9(1):50–54PubMedCrossRef Kollek R, van Aken J, Feuerstein G, Schmedders M (2006) Pharmacogenetics, adverse drug reactions and public health. Community Genet 9(1):50–54PubMedCrossRef
49.
go back to reference Stipp D (2000) A DNA tragedy. Fortune 142(10):170–174, 178, 180 passimPubMed Stipp D (2000) A DNA tragedy. Fortune 142(10):170–174, 178, 180 passimPubMed
50.
go back to reference Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F (2007) Concentrations of tramadol and o-desmethyltramadol enantiomers in different cyp2d6 genotypes. Clin Pharmacol Ther 82(1):41–47PubMedCrossRef Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F (2007) Concentrations of tramadol and o-desmethyltramadol enantiomers in different cyp2d6 genotypes. Clin Pharmacol Ther 82(1):41–47PubMedCrossRef
51.
go back to reference Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J (2004) Codeine intoxication associated with ultrarapid cyp2d6 metabolism. N Engl J Med 351(27):2827–2831PubMedCrossRef Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J (2004) Codeine intoxication associated with ultrarapid cyp2d6 metabolism. N Engl J Med 351(27):2827–2831PubMedCrossRef
52.
go back to reference Koski A (2005) Interpretation of postmortem toxicology results: pharmacogenetics and drug–alcohol interaction. PhD thesis, University of Helsinki, Helsinki, Finland Koski A (2005) Interpretation of postmortem toxicology results: pharmacogenetics and drug–alcohol interaction. PhD thesis, University of Helsinki, Helsinki, Finland
53.
54.
go back to reference Levisky JA, Bowerman DL, Jenkins WW, Johnson DG, Karch SB (2001) Drugs in postmortem adipose tissues: evidence of antemortem deposition. Forensic Sci Int 121(3):157–160PubMedCrossRef Levisky JA, Bowerman DL, Jenkins WW, Johnson DG, Karch SB (2001) Drugs in postmortem adipose tissues: evidence of antemortem deposition. Forensic Sci Int 121(3):157–160PubMedCrossRef
56.
go back to reference Wagner M (2003) Stability of drugs of abuse in biological specimens. MSc thesis, Columbia Pacific University Wagner M (2003) Stability of drugs of abuse in biological specimens. MSc thesis, Columbia Pacific University
57.
go back to reference Sporer KA (1995) The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf 13(2):94–104PubMedCrossRef Sporer KA (1995) The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf 13(2):94–104PubMedCrossRef
58.
go back to reference Gillman PK (2007) Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 151(6):737–748PubMedCrossRef Gillman PK (2007) Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 151(6):737–748PubMedCrossRef
59.
60.
go back to reference Fisher AA, Davis MW (2002) Serotonin syndrome caused by selective serotonin reuptake-inhibitors–metoclopramide interaction. Ann Pharmacother 36(1):67–71PubMedCrossRef Fisher AA, Davis MW (2002) Serotonin syndrome caused by selective serotonin reuptake-inhibitors–metoclopramide interaction. Ann Pharmacother 36(1):67–71PubMedCrossRef
61.
go back to reference Bush E, Miller C, Friedman I (2006) A case of serotonin syndrome and mutism associated with methadone. J Palliat Med 9(6):1257–1259PubMedCrossRef Bush E, Miller C, Friedman I (2006) A case of serotonin syndrome and mutism associated with methadone. J Palliat Med 9(6):1257–1259PubMedCrossRef
Metadata
Title
Deaths involving contraindicated and inappropriate combinations of serotonergic drugs
Authors
Jennifer L. Pilgrim
Dimitri Gerostamoulos
Olaf H. Drummer
Publication date
01-11-2011
Publisher
Springer-Verlag
Published in
International Journal of Legal Medicine / Issue 6/2011
Print ISSN: 0937-9827
Electronic ISSN: 1437-1596
DOI
https://doi.org/10.1007/s00414-010-0536-3

Other articles of this Issue 6/2011

International Journal of Legal Medicine 6/2011 Go to the issue